Alta Immuno

A Platform Technology Company for the Expanded Use of Organs and Cells in Transplantation Surgery and Regenerative Medicine

Background

A new platform technology has been developed that imitates the maternal immune system in preventing the rejection of a foetus during pregnancy. The technology can be utilised to reduce the need for immunosuppressants in transplantation immunology (e.g. kidney) and potentially a range of areas in regenerative medicine related treatments (e.g. bone marrow, placental cells and other stem cells).

Problem

Although kidney, heart and other transplants have been carried out for many years the issue of rejection still remains and the continuous use of immunosuppressants is required with adverse side effects and reduced effectiveness over time. In addition, many organs are unused due to tissue compatibility issues and wastage levels are high. Similar issues exist in cellular therapies

Solution

A new protein-based therapeutic has been developed that reduce the need for immunosuppressants.

Market Potential

The market potential for use in the first application, kidney transplantation, is approximately $300 million per annum.

Status

NHSIL provided funding for the proof-of-science, patenting and in vitro testing of the protein. The molecule is currently in preclinical testing.

Further information

Please contact David Chilvers, Chief Executive, NHS Innovations London Ltd.